Tempest Therapeutics (TPST) director awarded 25,000 stock options at $1.27 strike

Rhea-AI Filing Summary

Tempest Therapeutics director Richey William Drake received a grant of stock options for 25,000 shares of Common Stock. The options have an exercise price of $1.27 per share and expire on June 4, 2036. They vest over three years, with one-third on the first anniversary and the rest in equal monthly installments, contingent on continued service. Following this grant, he holds 25,000 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Richey William Drake

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 25,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 25,000 options Exercise price: $1.27 per share Underlying shares: 25,000 shares +2 more

5 metrics

Options granted 25,000 options Stock Option (right to buy) granted to director

Exercise price $1.27 per share Conversion/exercise price of stock options

Underlying shares 25,000 shares Common Stock underlying granted options

Expiration date June 4, 2036 Option expiration for Drake’s grant

Holdings after transaction 25,000 options Total derivative securities following grant

Key Terms

Stock Option (right to buy), exercise price, vest over a three-year period, equal monthly installments, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "1.2700" per share as exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest over a three-year period financial

"The shares subject to each such stock option will vest over a three-year period"

equal monthly installments financial

"the remainder of the award vesting in equal monthly installments thereafter"

continued service financial

"thereafter, subject to the Reporting Person's continued service"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Richey William Drake

(Last) (First) (Middle)

9 LUDLOW ST

(Street)

BOSTON MASSACHUSETTS 02129

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tempest Therapeutics, Inc. [ TPST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.27	06/04/2026		A		25,000		(1)	06/04/2036	Common Stock	25,000	$0.00	25,000	D

Explanation of Responses:

1. The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.

	/s/ William Drake Richey	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Tempest Therapeutics (TPST) director Richey William Drake receive in this Form 4?

Richey William Drake received a grant of stock options for 25,000 shares of Tempest Therapeutics common stock. These options are a form of equity compensation that give him the right to buy shares at a fixed price if they vest and he chooses to exercise.

What is the exercise price of the Tempest Therapeutics (TPST) options granted to Drake?

The stock options granted to Drake have an exercise price of $1.27 per share. This means he can buy Tempest Therapeutics common stock at that price once the options vest, regardless of the market price at that future time.

How do the Tempest Therapeutics (TPST) stock options granted to Drake vest?

The options vest over three years. One-third of the 25,000-share award vests on the first anniversary of the grant date, with the remaining two-thirds vesting in equal monthly installments thereafter, conditioned on Drake’s continued service with Tempest Therapeutics.

When do the Tempest Therapeutics (TPST) options granted to Drake expire?

The stock options granted to Drake expire on June 4, 2036. After this expiration date, any unexercised options become void, so he must decide whether to exercise vested options before that deadline if it is economically attractive.

How many Tempest Therapeutics (TPST) derivative securities does Drake hold after this transaction?

After this grant, Drake holds 25,000 stock options related to Tempest Therapeutics common stock. These options represent the right, but not the obligation, to purchase 25,000 shares at the fixed exercise price of $1.27 per share, subject to vesting.